Perseus Proteomics Inc. (TYO:4882)

Market Cap	5.53B
Revenue (ttm)	111.39M
Net Income (ttm)	-898.75M
Shares Out	14.74M
EPS (ttm)	-66.34
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,665,500
Average Volume	1,789,350
Open	400.00
Previous Close	375.00
Day's Range	386.00 - 412.00
52-Week Range	298.00 - 1,113.00
Beta	0.72
RSI	36.26
Earnings Date	May 15, 2025

About Perseus Proteomics

Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell;...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2001
• Employees: 25
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4882

Financial Performance

In 2023, Perseus Proteomics's revenue was 100.00 million, an increase of 6.38% compared to the previous year's 94.00 million. Losses were -1.10 billion, 40.5% more than in 2022.